HER2-negative Breast Cancer Clinical Trials in Chicago, Illinois

7 studies are recruiting for her2-negative breast cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

2. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

3. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

   The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   11 in total

   Run by

   Ana C Garrido-Castro, MD

   See if you can join NCT06533826 on ClinicalTrials.gov

4. Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

   This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Locations

   21 in total

   Run by

   Oana Danciu

   See if you can join NCT05467891 on ClinicalTrials.gov

5. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

   This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epiderm…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Locations

   7 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT05029999 on ClinicalTrials.gov

6. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov

7. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

   This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   37 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT05216432 on ClinicalTrials.gov